Mineralys Therapeutics (Nasdaq: MLYS) announced that its management will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, held September 8-10, 2026. The company is scheduled for a fireside chat on Wednesday, September 9, 2026 at 4:30 p.m. EDT, with a live webcast available via its Investor Relations website.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
A prior conference-participation announcement was followed by a 7.47% 24-hour move, but other recent...
Analysis
A prior conference-participation announcement was followed by a 7.47% 24-hour move, but other recent reactions were negative. This event adds a scheduled investor touchpoint; Net Selling insider activity is a separate risk to monitor.
Management participation in Goldman Sachs healthcare conference fireside chat
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Prior reactions were mixed, including a 7.47% gain after conference participation and declines after recent earnings and inducement-award announcements.
"target hypertension and aldosterone-related adverse outcomes"
Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.
comorbid conditionsmedical
"aldosterone-related adverse outcomes in comorbid conditions"
Two or more medical conditions that occur in the same person at the same time, such as diabetes alongside heart disease. Comorbid conditions matter to investors because they affect how patients respond to treatments, complicate clinical trial design and regulatory review, influence healthcare costs and prescribing patterns, and therefore shape the commercial value and risks of drugs, devices, and health services — like multiple issues changing the outcome of a single repair job.
obstructive sleep apneamedical
"chronic kidney disease, obstructive sleep apnea and other diseases"
Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.
RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 2026.
A live webcast of this fireside chat can also be accessed on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.
When will Mineralys Therapeutics (MLYS) present at the Wells Fargo 21st Annual Healthcare Conference in 2026?
Mineralys Therapeutics will participate in a fireside chat on Wednesday, September 9, 2026 at 4:30 p.m. EDT. According to Mineralys Therapeutics, this session is part of the Wells Fargo 21st Annual Healthcare Conference in Boston, scheduled from September 8-10, 2026.
What is the format of Mineralys Therapeutics (MLYS) appearance at the Wells Fargo 2026 Healthcare Conference?
Mineralys Therapeutics will appear in a fireside chat format at the conference. According to Mineralys Therapeutics, this discussion is scheduled for September 9, 2026 at 4:30 p.m. EDT and will be accessible to investors via a live webcast on the company’s Investor Relations website.
How can investors access the Mineralys Therapeutics (MLYS) webcast from the Wells Fargo 21st Annual Healthcare Conference?
Investors can access a live webcast of the fireside chat through the Mineralys Therapeutics Investor Relations website. According to Mineralys Therapeutics, the link will be available on the “News & Events” page, allowing online viewing of the September 9, 2026 4:30 p.m. EDT session.
Where is the Wells Fargo 21st Annual Healthcare Conference featuring Mineralys Therapeutics (MLYS) being held?
The conference featuring Mineralys Therapeutics is being held in Boston from September 8-10, 2026. According to Mineralys Therapeutics, its management will participate in a scheduled fireside chat on September 9, 2026 at 4:30 p.m. EDT, accessible via webcast for investors.
Why is Mineralys Therapeutics (MLYS) participating in the Wells Fargo 21st Annual Healthcare Conference?
Mineralys Therapeutics is participating to have management join a fireside chat with investors and stakeholders. According to Mineralys Therapeutics, the appearance at the Wells Fargo 21st Annual Healthcare Conference in Boston includes a webcasted session on September 9, 2026 at 4:30 p.m. EDT.
